New cancer treatment faces talent shortage in radiopharmaceuticals sector

A new type of cancer treatment, known as radiopharmaceuticals, is gaining attention for its ability to target cancer cells more precisely than traditional radiation therapy. This method combines radioactive isotopes with components that direct the treatment to tumors. Despite the growing interest, there is a significant shortage of skilled professionals in this field. Many drug developers and healthcare providers are struggling to find the necessary expertise to advance these therapies. In the past five years, over a dozen startups have emerged in this area, with four being acquired by major pharmaceutical companies for over $1 billion each. Analysts expect increased activity in the sector by 2025.